Nonalcoholic fatty liver disease: daily aspirin use tied to lower risk for fibrosis progression

  • Simon TG & al.
  • Clin Gastroenterol Hepatol
  • 9 May 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with biopsy-proven non-alcoholic fatty liver disease (NAFLD), daily aspirin use was inversely associated with prevalent non-alcoholic steatohepatitis (NASH) and fibrosis.
  • In patients with early-stage fibrosis, daily aspirin use was associated with significantly lower risk for progressing to advanced fibrosis in a duration-dependent manner

Why this matters

  • Although preclinical data suggest that aspirin may protect against incidence and progression of NAFLD, clinical evidence focusing on aspirin use in NAFLD is limited.
  • Findings add to the growing literature supporting the potential hepatoprotective effects of aspirin in patients with NAFLD.

Study design

  • A prospective cohort study of 361 patients with biopsy-confirmed NAFLD who were revaluated every 3-12 months for incident advanced fibrosis defined using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score and aspartate aminotransferase to platelet ratio indices).
  • Data on frequency and duration of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) use were collected.
  • Funding: National Institutes of Health and others.

Key results

  • Of 361 patients, 151 were daily aspirin users and 210 were non-regular users.
  • Compared with non-regular users, daily aspirin users were at lower risk for:
    • NASH (adjusted OR [aOR], 0.68; 95% CI, 0.37-0.89),
    • fibrosis (aOR, 0.54; 95% CI, 0.31-0.82) and
    • incident advanced fibrosis (Stage, 3-4; adjusted HR [aHR], 0.63; 95% CI, 0.43-0.85)
  • Compared with non-regular use, 2 to
  • Use of non-aspirin NSAIDs was not associated with reduced risk for incident advanced fibrosis (aHR, 0.93; 95% CI, 0.81-1.05).

Limitations

  • Risk of residual confounding.
  • Possible recall bias and exposure misclassification because of self-reported data on aspirin use.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit